IN THIS ARTICLE

Citations

1. Tremlett H, et al. (2010). New perspectives in the natural history of multiple sclerosis. Neurology, 74(24): 2004–2015.

2. Ropper AH, Samuels MA (2009). Multiple sclerosis and allied demyelinative diseases. In Adams and Victor's Principles of Neurology, 9th ed., pp. 874–903. New York: McGraw-Hill.

3. National Clinical Advisory Board of the National Multiple Sclerosis Society (2008). Disease Management Consensus Statement. New York: National Multiple Sclerosis Society. Available online: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/expert-opinion-papers/index.aspx.

4. Burt RK, et al. (2009). Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurology, 8(3): 244–253.

5. Fassas A, et al. (2011). Long-term results of stem cell transplantation for MS: A single-center experience. Neurology, 76(12): 1066–1070.

Other Works Consulted

• Burton JM, et al. (2009). Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database of Systematic Reviews (3).

• Cortese I, et al. (2011). Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 76(3): 294–300.

• Courtney AM, et al. (2009). Multiple sclerosis. Medical Clinics of North America, 93(2): 451–476.

• Fox RJ, Arnold DL (2009). Seeing injectable MS therapies differently: They are more similar than different. Neurology, 72(23): 1972–1973.

• Giesser B (2010). Reproductive Issues in Persons With Multiple Sclerosis. Clinical Bulletin: Information Health Professionals. Available online: http://www.nationalmssociety.org/for-professionals/healthcare-professionals/publications/clinical-bulletins/index.aspx.

• Goodin DS, et al. (2008, reaffirmed 2010). Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 68(13): 977–984.

• Grossman P, et al. (2010). MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial. Neurology, 75(13): 1141–1149.

• Kelly VM, et al. (2009). Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology, 73(22): 1831–1836.

• Marriott JJ, et al. (2010). Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 74(18): 1463–1470.

• McDonald WI, et al. (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50(1): 121–127.

• Polman CH, et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Annals of Neurology, 58(6): 840–846.

• Polman CH, et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine, 354(9): 899–910.

• Polman CH, et al. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69(2): 292–302.

• Yousry TA, et al. (2006). Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England Journal of Medicine, 354(9): 924–933.